Craig Hallum lowered shares of Senseonics (NYSEAMERICAN:SENS) from a buy rating to a hold rating in a report published on Wednesday, Briefing.com Automated Import reports. They currently have $2.50 price objective on the stock.
A number of other research firms have also recently weighed in on SENS. Piper Jaffray Companies set a $2.00 target price on shares of Senseonics and gave the company a hold rating in a research note on Wednesday, September 4th. Stifel Nicolaus assumed coverage on shares of Senseonics in a research note on Tuesday, October 22nd. They issued a buy rating and a $2.00 target price on the stock. Canaccord Genuity cut shares of Senseonics from a buy rating to a hold rating and dropped their target price for the company from $2.00 to $1.00 in a research note on Wednesday. Finally, BTIG Research reiterated a buy rating and issued a $2.00 target price on shares of Senseonics in a research note on Sunday, August 11th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the stock. The company currently has an average rating of Hold and an average target price of $1.90.
Senseonics stock traded down $0.01 during midday trading on Wednesday, hitting $0.87. 1,516,045 shares of the stock were exchanged, compared to its average volume of 1,759,505. Senseonics has a 52-week low of $0.80 and a 52-week high of $3.60. The business’s 50-day moving average price is $1.07 and its 200-day moving average price is $1.79.
In other Senseonics news, CEO Timothy T. Goodnow purchased 88,500 shares of the stock in a transaction dated Monday, September 9th. The shares were bought at an average price of $1.10 per share, with a total value of $97,350.00. Insiders own 34.10% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of SENS. Bank of Montreal Can increased its holdings in Senseonics by 236.4% during the 2nd quarter. Bank of Montreal Can now owns 14,513 shares of the company’s stock worth $29,000 after acquiring an additional 10,199 shares during the period. D. E. Shaw & Co. Inc. bought a new stake in Senseonics during the 2nd quarter worth approximately $33,000. Centaurus Financial Inc. increased its holdings in Senseonics by 40,551.2% during the 2nd quarter. Centaurus Financial Inc. now owns 16,667 shares of the company’s stock worth $34,000 after acquiring an additional 16,626 shares during the period. Royal Bank of Canada increased its holdings in Senseonics by 596.9% during the 2nd quarter. Royal Bank of Canada now owns 29,269 shares of the company’s stock worth $60,000 after acquiring an additional 25,069 shares during the period. Finally, Commonwealth Equity Services LLC increased its holdings in Senseonics by 194.0% during the 3rd quarter. Commonwealth Equity Services LLC now owns 29,664 shares of the company’s stock worth $29,000 after acquiring an additional 19,574 shares during the period. 30.66% of the stock is currently owned by institutional investors.
Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.
Recommended Story: Outstanding Shares
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.